Restoring E-cadherin Expression by Natural Compounds for Anticancer Therapies in Genital and Urinary Cancers
Author(s) -
Yizuo Song,
Miaomiao Ye,
Junhan Zhou,
Zhiwei Wang,
Xueqiong Zhu
Publication year - 2019
Publication title -
molecular therapy — oncolytics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.424
H-Index - 23
ISSN - 2372-7705
DOI - 10.1016/j.omto.2019.04.005
Subject(s) - metastasis , cancer , cancer research , in vivo , epithelial–mesenchymal transition , cadherin , medicine , urinary system , pharmacology , biology , microbiology and biotechnology , cell , genetics
E-cadherin plays a pivotal role in cancer progression, including the epithelial-mesenchymal transition (EMT) process and tumor metastasis. Loss of E-cadherin contributes to enhanced invasion and metastasis in human cancers. Therefore, restoring E-cadherin could be a potential approach for cancer therapy. Multiple natural compounds have been shown to possess anti-tumor activities through the regulation of key molecules in signaling pathways, including E-cadherin. In this review, we describe the numerous compounds that restore the expression of E-cadherin in genital and urinary malignancies. We further discuss the potential anti-tumor molecular mechanisms of these agents as the activators of E-cadherin in genital and urinary cancers. Although these compounds exhibit their potential to inhibit the development and progression of cancers, there are several challenges to developing them as therapeutic drugs for cancer patients. Poor bioavailability in vivo is the main disadvantage of these compounds. Modification of compound structures has produced actual improvements in bioavailability. Nanoparticle-based delivery systems could be useful to deliver the agents to targeted organs. These compounds could be new promising therapeutic agents for the treatment of human genital and urinary cancers. Further investigations are required to determine the safety and side effects of natural compounds using animal models prior to clinical trials.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom